What is GLMD (GLMD) stock price today?

GLMD (GLMD) is currently trading at $0.62, up 3.67% today.

What is GLMD P/E ratio?

GLMD's P/E ratio is -0.25. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GLMD return on equity (ROE)?

GLMD's return on equity (ROE) is -62.50%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GLMD's market cap?

GLMD has a market capitalization of $5.13M.

NCM · Biotechnology

GLMD (GLMD) Stock

$0.62 +3.67% NCM: GLMD Healthcare

Valuation

Metric	Value
Price	$0.62
Market Cap	$5.13M
P/E Ratio	-0.25
P/B Ratio	0.21
P/S Ratio	0.00
EPS (TTM)	$-2.39
52-Week High	$2.34
52-Week Low	$0.41
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-62.50%
ROA	-52.63%
ROCE	-56.25%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	6.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-33.0M	$-18.0M	$-7.0M	$-6.0M	$-9.0M
Net Profit	$-32.0M	$-18.0M	$-7.0M	$-8.0M	$-10.0M
EPS	$-19.48	$-11.08	$-29.95	$-8.08	$-2.39
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$37.0M	$17.0M	$17.0M	$19.0M	$19.0M
Total Liabilities	$6.0M	$3.0M	$3.0M	$2.0M	$3.0M
Cash	$3.0M	$2.0M	$3.0M	$5.0M	$4.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) InvestorsHub · Jul 16, 2026 Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol PR Newswire · Jul 16, 2026 Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal MT Newswires · Jun 22, 2026 Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition PR Newswire · Jun 22, 2026 Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market PR Newswire · Jun 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-33.0M	$-19.0M	$-6.0M	$-6.0M	$-6.0M
Investing Cash Flow	$11.0M	$18.0M	$1.0M	$-1.0M	$-3.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-4.0M	$-1.0M	$1.0M	$2.0M	$-1.0M
Free Cash Flow	$-33.0M	$-19.0M	$-6.0M	$-6.0M	$-6.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-190.82%
Quick Ratio	6.55
Interest Coverage	—
Return 1Y	-75.07%
Return 3Y	-97.05%
Return 5Y	-99.89%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BDRXBiodexa Pharmaceuticals Plc	$1.71	-3.39%	0.00	$1.28M	0.00%
BIVI	$1.52	+6.29%	-0.11	$11.46M	0.00%
CMMBChemomab Therapeutics Ltd.	$1.43	-2.72%	-1.30	$8.80M	0.00%
ELAB	$0.92	+2.21%	0.00	$1.78M	0.00%
INM	$1.47	-2.00%	-0.18	$2.66M	0.00%

About GLMD

GLMD is led by CEO Allen Baharaff, employs 3 people, headquartered in IL, publicly traded since 2014.

GLMD stock trades at $0.62 with a market capitalization of $5.13M. The stock is valued at a price-to-earnings (P/E) ratio of -0.25, price-to-book of 0.21, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.41 and $2.34, and currently trades 73.5% below its 52-week high.

On profitability, GLMD generates a return on equity (ROE) of -62.50%, return on capital employed of -56.25%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides